Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials
Monoclonal antibodies (mAbs) that block the programmed death 1 (PD-1) or programmed death-ligand 1 (PD-L1) receptors are the most clinically advanced tumor immunotherapies. Given the broad antitumor efficacy and novel mechanism of action, numerous combinatorial approaches incorporating PD-1/PD-L1 bl...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-04-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/2162402X.2017.1408744 |
| _version_ | 1819064261758943232 |
|---|---|
| author | C. Bryce Johnson Shwe Y. Win |
| author_facet | C. Bryce Johnson Shwe Y. Win |
| author_sort | C. Bryce Johnson |
| collection | DOAJ |
| description | Monoclonal antibodies (mAbs) that block the programmed death 1 (PD-1) or programmed death-ligand 1 (PD-L1) receptors are the most clinically advanced tumor immunotherapies. Given the broad antitumor efficacy and novel mechanism of action, numerous combinatorial approaches incorporating PD-1/PD-L1 blockade have been suggested; herein we present a comprehensive analysis of these clinical trials. We queried clinicaltrials.gov for all PD-1/PD-L1 mAbs administered for cancer therapy with an end date of 4/30/2017. A total of 1,218 clinical trials met our search criteria. These trials have a planned enrollment of 227,190 patients, and approximately half (493) were initiated in 2016 alone. Of these over 1,200 trials, 916 combine PD-1/PD-L1 blockade with at least one additional therapy, ranging from traditional treatment modalities like surgery and chemoradiation to newer therapies like small molecule inhibitors and other immunotherapies. The staggering proliferation of clinical trials combining PD-1/PD-L1 blockade with disparate treatments necessitates careful accounting to maximize efficiency and highlight areas of unmet needs. We believe our analysis provides this data and expect it will facilitate the design of future clinical trials in this burgeoning area of oncology research. |
| first_indexed | 2024-12-21T15:27:46Z |
| format | Article |
| id | doaj.art-f62d36ea28944ebd9c48e304cea33c3e |
| institution | Directory Open Access Journal |
| issn | 2162-402X |
| language | English |
| last_indexed | 2024-12-21T15:27:46Z |
| publishDate | 2018-04-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj.art-f62d36ea28944ebd9c48e304cea33c3e2022-12-21T18:58:51ZengTaylor & Francis GroupOncoImmunology2162-402X2018-04-017410.1080/2162402X.2017.14087441408744Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trialsC. Bryce Johnson0Shwe Y. Win1MedStar Harbor HospitalMedStar Harbor HospitalMonoclonal antibodies (mAbs) that block the programmed death 1 (PD-1) or programmed death-ligand 1 (PD-L1) receptors are the most clinically advanced tumor immunotherapies. Given the broad antitumor efficacy and novel mechanism of action, numerous combinatorial approaches incorporating PD-1/PD-L1 blockade have been suggested; herein we present a comprehensive analysis of these clinical trials. We queried clinicaltrials.gov for all PD-1/PD-L1 mAbs administered for cancer therapy with an end date of 4/30/2017. A total of 1,218 clinical trials met our search criteria. These trials have a planned enrollment of 227,190 patients, and approximately half (493) were initiated in 2016 alone. Of these over 1,200 trials, 916 combine PD-1/PD-L1 blockade with at least one additional therapy, ranging from traditional treatment modalities like surgery and chemoradiation to newer therapies like small molecule inhibitors and other immunotherapies. The staggering proliferation of clinical trials combining PD-1/PD-L1 blockade with disparate treatments necessitates careful accounting to maximize efficiency and highlight areas of unmet needs. We believe our analysis provides this data and expect it will facilitate the design of future clinical trials in this burgeoning area of oncology research.http://dx.doi.org/10.1080/2162402X.2017.1408744cancer immunotherapyclinical trialspd-1pd-l1t cell checkpoint inhibitors |
| spellingShingle | C. Bryce Johnson Shwe Y. Win Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials OncoImmunology cancer immunotherapy clinical trials pd-1 pd-l1 t cell checkpoint inhibitors |
| title | Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials |
| title_full | Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials |
| title_fullStr | Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials |
| title_full_unstemmed | Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials |
| title_short | Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials |
| title_sort | combination therapy with pd 1 pd l1 blockade an overview of ongoing clinical trials |
| topic | cancer immunotherapy clinical trials pd-1 pd-l1 t cell checkpoint inhibitors |
| url | http://dx.doi.org/10.1080/2162402X.2017.1408744 |
| work_keys_str_mv | AT cbrycejohnson combinationtherapywithpd1pdl1blockadeanoverviewofongoingclinicaltrials AT shweywin combinationtherapywithpd1pdl1blockadeanoverviewofongoingclinicaltrials |